Brivaracetam does not modulate ionotropic channels activated by glutamate, γ‐aminobutyric acid, and glycine in hippocampal neurons

Summary Brivaracetam ( BRV ) is a selective, high‐affinity ligand for synaptic vesicle protein 2A ( SV 2A), recently approved as adjunctive treatment for drug‐refractory partial‐onset seizures in adults. BRV binds SV 2A with higher affinity than levetiracetam ( LEV ), and was shown to have a differential interaction with SV 2A. Because LEV was reported to interact with multiple excitatory and inhibitory ligand‐gated ion channels and that may impact its pharmacological profile, we were interested in determining whether BRV directly modulates inhibitory and excitatory ionotropic receptors in central neurons. Voltage‐clamp experiments were performed in primary cultures of mouse hippocampal neurons. At a supratherapeutic concentration of 100 μ m , BRV was devoid of any direct effect on currents gated by γ‐aminobutyric acidergic type A, glycine, kainate, N ‐methyl‐ d ‐aspartate, and α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid. Similarly to LEV , BRV reveals a potent ability to oppose the action of negative modulators on the inhibitory receptors. In conclusion, these results show that BRV contrasts with LEV by not displaying any direct action on inhibitory or excitatory postsynaptic ligand‐gated receptors at therapeutic concentrations and thereby support BRV 's role as a selective SV 2A ligand. These findings add further evidence to the validity of SV 2A as a relevant antiepileptic drug target and emphasize the potential for exploring further presynaptic mechanisms as a novel approach to antiepileptic drug discovery.